Liquid Biopsy Using Methylation Sequencing for Lung Cancer
NCT04253509 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 280
Last updated 2022-02-08
Summary
This study aims to investigate the utility of circulating tumor DNA (ctDNA) methylation sequencing in the diagnosis of primary lung cancer.
Conditions
- Lung Cancer
- Diagnoses Disease
Interventions
- DIAGNOSTIC_TEST
-
Circulating Tumor DNA Methylation Sequencing
Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.
Sponsors & Collaborators
-
EDGC Inc.
collaborator UNKNOWN -
Samsung Medical Center
lead OTHER
Principal Investigators
-
Sang-Won Um, MD, PhD · Samsung Medical Center
Eligibility
- Min Age
- 15 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-02-03
- Primary Completion
- 2022-01-31
- Completion
- 2022-01-31
Countries
- South Korea
Study Locations
More Related Trials
-
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
NCT04814407 ·Status: RECRUITING
-
Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment
NCT03244904 ·Status: UNKNOWN
-
CirculAting Tumor DNA in Patients DIagnosed With Lung Metastasis From Colorectal Cancer: candiDate Selection for Local AblaTive thErapy
NCT04704960 ·Status: UNKNOWN
-
Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery
NCT05648370 ·Status: UNKNOWN
-
Gene Mutations in Non-Small Cell Lung Cancer Cells
NCT00977509 ·Status: UNKNOWN
-
Practical Usability of EGFR Mutation Detection in ctDNA From Resectable NSCLC
NCT04922073 ·Status: UNKNOWN
-
A Comprehensive Evaluation of Circulating Tumor DNA and Circulating Tumor Cells as a Predictive Marker in Lung Cancer
NCT04254497 ·Status: COMPLETED
-
Study of Tumor Samples From Patients With Lung Cancer
NCT00900328 ·Status: COMPLETED
-
Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer
NCT01139944 ·Status: COMPLETED
-
Whether Sputum Can Serve as an Alternative Source for Liquid Biopsy in Patients With Lung Cancer
NCT05034445 ·Status: COMPLETED
-
Molecular Diagnosis of Lung Cancer Via Bronchoscopy: The Significance of Bronchial Liquid Biopsy (ctDNA and ctRNA)
NCT06228508 ·Status: NOT_YET_RECRUITING
-
Liquid Biopsy for Early Non-small Lung Cancer Detection
NCT05462795 ·Status: COMPLETED
-
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
NCT00471978 ·Status: RECRUITING
-
AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy
NCT07009769 ·Status: COMPLETED
-
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
NCT03172156 ·Status: COMPLETED
-
Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer
NCT06301295 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA
NCT02833467 ·Status: UNKNOWN
-
Analysis of Plasma Tumor DNA in Lung Cancer Patients
NCT01930474 ·Status: UNKNOWN
-
Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer
NCT04156360 ·Status: UNKNOWN
-
Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma Derived Exosome
NCT04529915 ·Status: UNKNOWN
-
NGS-based Comprehensive Genomic ctDNA Panel in NSCLC With Immunotherapy
NCT04636047 ·Status: UNKNOWN
-
Feasibility of Bronchial Washing Fluid for Molecular Testing With Next Generation Sequencing in Lung Cancer
NCT06141005 ·Status: COMPLETED ·Phase: NA
-
Genotyping of Non-small Cell Lung Cancer
NCT02002117 ·Status: UNKNOWN
-
An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma
NCT05759325 ·Status: NOT_YET_RECRUITING
-
Circulating Tumor DNA in Patients at High Risk for Lung Cancer
NCT02715102 ·Status: TERMINATED